The MarketWatch News Department was not involved in the creation of this content. -- Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results